Background and aims Molnupiravir is a newer oral antiviral drug that has recently been
tested in COVID-19. We aim to conduct a systematic review of literature to find out the …

Background The prognostic significance of diabetes mellitus (DM) in patients with
coronavirus 2019 disease (COVID-19) remains unknown. Objectives To assess the risk of …

Background Oral nirmatrelvir/ritonavir (Paxlovid) aims to avoid severe COVID‐19 in
asymptomatic people or those with mild symptoms, thereby decreasing hospitalization and …

Objectives We evaluated the clinical, virological and safety outcomes of lopinavir/ritonavir,
lopinavir/ritonavir–interferon (IFN)-β-1a, hydroxychloroquine or remdesivir in comparison to …

Several randomized controlled trials and real‐world cohort studies have demonstrated the
efficacies of nirmatrelvir plus ritonavir (NMV‐r) and molnupiravir (MOV) in at‐risk patients …

Twonewantiviralmedications, ritonavir-boostednirmatrelvir (Paxlovid, ie, nirmatrelvir-
ritonavir) and molnupiravir (Lagevrio), are currently availableintheUSunderemergencyuseautho …

Objectives This retrospective cohort study assessed the clinical effectiveness of
nirmatrelvirplus ritonavir (NMV-r) in treating COVID-19 in patients with liver cirrhosis (LC) …

ABSTRACT Background Ritonavir-boosted Nirmatrelvir (NMV-r), a protease inhibitor with in
vitro activity against SARS-CoV-2, has been shown to reduce risk of progression to severe …

Aim: To evaluate the efficacy and safety of lopinavir–ritonavir (LPV/r) therapy in treating
hospitalized COVID-19 patients. Materials & methods: Data from randomized and …

Abstract Favipiravir (FVP), lopinavir/ritonavir (LPV/RTV), and interferon‐beta (INF‐beta) are
considered as potential treatments for COVID‐19. We examined the efficacy and safety of …